Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.
Aubrais R, Bouabdallah K, Chartier L, Herbaux C, Banos A, Brice P, Sibon D, Schiano JM, Cluzeau T, Laribi K, Le Calloch R, Bellal M, Delapierre B, Daguindau N, Amorim S, Agbetiafa K, Chauchet A, Besson C, Durot E, Bonnet C, Fouillet L, Bijou F, Tournilhac O, Gaulard P, Parrens MC, Damaj G. Aubrais R, et al. Among authors: herbaux c. Blood Adv. 2023 Oct 10;7(19):5733-5742. doi: 10.1182/bloodadvances.2022008524. Blood Adv. 2023. PMID: 36477770 Free PMC article.
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
Cartron G, Bachy E, Tilly H, Daguindau N, Pica GM, Bijou F, Mounier C, Clavert A, Damaj GL, Slama B, Casasnovas O, Houot R, Bouabdallah K, Sibon D, Fitoussi O, Morineau N, Herbaux C, Gastinne T, Fornecker LM, Haioun C, Launay V, Araujo C, Benbrahim O, Sanhes L, Gressin R, Gonzalez H, Morschhauser F, Ternant D, Xerri L, Tarte K, Pranger D. Cartron G, et al. Among authors: herbaux c. J Clin Oncol. 2023 Jul 1;41(19):3523-3533. doi: 10.1200/JCO.22.02327. Epub 2023 Apr 18. J Clin Oncol. 2023. PMID: 37071836 Free article. Clinical Trial.
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.
Chemlal D, Varlet E, Machura A, Ovejero S, Requirand G, Robert N, Cartron G, Alaterre E, Bret C, Vincent L, Herbaux C, Cavalli G, Bruyer A, De Boussac H, Moreaux J. Chemlal D, et al. Among authors: herbaux c. Leukemia. 2023 Sep;37(9):1925-1928. doi: 10.1038/s41375-023-01983-0. Epub 2023 Aug 2. Leukemia. 2023. PMID: 37532787 Free PMC article. No abstract available.
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.
Lemoine J, Bachy E, Cartron G, Beauvais D, Gastinne T, Di Blasi R, Rubio MT, Guidez S, Mohty M, Casasnovas RO, Joris M, Castilla-Llorente C, Haioun C, Hermine O, Loschi M, Carras S, Bories P, Fradon T, Herbaux C, Sesques P, Le Gouill S, Morschhauser F, Thieblemont C, Houot R. Lemoine J, et al. Among authors: herbaux c. Blood Adv. 2023 Nov 14;7(21):6589-6598. doi: 10.1182/bloodadvances.2023010624. Blood Adv. 2023. PMID: 37672383 Free PMC article.
Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.
Marouf A, Molinari N, Sibon D, Cottereau AS, Kanoun S, Antoine C, Debureaux PE, Cavalieri D, Fornecker LM, Casasnovas RO, Herbaux C, Amorim S, Rossi C, Bouscary D, Brice P, Ghesquieres H, Tamburini J, Deau B. Marouf A, et al. Among authors: herbaux c. Br J Haematol. 2023 Jul;202(2):379-383. doi: 10.1111/bjh.18859. Epub 2023 May 16. Br J Haematol. 2023. PMID: 37192755
[Moxetumomab pasudotox-Third line in Hairy cell leukemia].
Montes L, Herbaux C. Montes L, et al. Among authors: herbaux c. Bull Cancer. 2021 Dec;108(12):1073-1074. doi: 10.1016/j.bulcan.2021.07.011. Epub 2021 Nov 12. Bull Cancer. 2021. PMID: 34776118 French. No abstract available.
91 results